Sunshine Biopharma closes USD 6 million public offering with Series C warrants
Share
Listen to the news
Sunshine Biopharma closes USD 6 million public offering with Series C warrants
  • Sunshine Biopharma closed a public offering raising about $6 million in gross proceeds.
  • Deal included 12,000,000 common units or pre-funded units priced at $0.5, each bundled with two Series C warrants.
  • Series C warrants are exercisable immediately at an initial exercise price of $0.5, with a five-year term.
  • Full cash exercise of the warrants would generate up to about $12 million in additional gross proceeds.
  • Net proceeds are expected to fund general corporate purposes and working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605191205ACCESSWRNAPR_____1168255) on May 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending